{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=thalidomide&page=7", "query": { "intervention": "thalidomide", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 226, "total_pages": 23, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=thalidomide&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=thalidomide&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T09:15:30.598Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00113932", "title": "UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "High-Dose Density Therapy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2003-12", "completion_date": "2010-07", "has_results": false, "last_update_posted_date": "2011-09-02", "last_synced_at": "2026-10-17T09:15:30.598Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00113932" }, { "nct_id": "NCT00000812", "title": "A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Thalidomide in Subjects With HIV-1 Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": null, "completion_date": "2000-07", "has_results": false, "last_update_posted_date": "2021-10-28", "last_synced_at": "2026-10-17T09:15:30.598Z", "location_count": 6, "location_summary": "Aurora, Colorado • Minneapolis, Minnesota • New York, New York + 3 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000812" }, { "nct_id": "NCT00574080", "title": "UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Interim/Maintenance Dexamethasone", "type": "DRUG" }, { "name": "Induction/Consolidation Dexamethasone", "type": "DRUG" }, { "name": "Induction/Consolidation Cisplatin", "type": "DRUG" }, { "name": "Induction/Consolidation Adriamycin", "type": "DRUG" }, { "name": "InductionConsolidation Cyclophosphamide", "type": "DRUG" }, { "name": "Induction/Consolidation Etoposide", "type": "DRUG" }, { "name": "Induction Pegfilgrastim", "type": "DRUG" }, { "name": "Transplant 1 Dexamethasone", "type": "DRUG" }, { "name": "Transplant 1 Cisplatin", "type": "DRUG" }, { "name": "Transplant 1 Adriamycin", "type": "DRUG" }, { "name": "Transplant 1 Cyclophosphamide", "type": "DRUG" }, { "name": "Transplant 1 Etoposide", "type": "DRUG" }, { "name": "Transplant 1 Melphalan", "type": "DRUG" }, { "name": "Transplant 1 and 2 Pegfilgrastim", "type": "DRUG" }, { "name": "Autologous Peripheral Blood Stem Cell Transplant (ASCT)", "type": "PROCEDURE" }, { "name": "Transplant 2 Carmustine", "type": "DRUG" }, { "name": "Transplant 2 Etoposide", "type": "DRUG" }, { "name": "Transplant 2 Cytarabine", "type": "DRUG" }, { "name": "Transplant 2 Melphalan", "type": "DRUG" }, { "name": "Transplant 2 Dexamethasone", "type": "DRUG" }, { "name": "Transplant 1 and 2 Bortezomib", "type": "DRUG" }, { "name": "Transplant 1 and 2 Thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2006-07", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2017-11-20", "last_synced_at": "2026-10-17T09:15:30.598Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00574080" }, { "nct_id": "NCT00014443", "title": "Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "thalidomide", "type": "DRUG" }, { "name": "topotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rush University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 5, "start_date": "2000-08", "completion_date": "2003-12", "has_results": false, "last_update_posted_date": "2023-01-09", "last_synced_at": "2026-10-17T09:15:30.598Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00014443" }, { "nct_id": "NCT00507416", "title": "Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 502, "start_date": "2007-06", "completion_date": "2013-03", "has_results": true, "last_update_posted_date": "2014-05-01", "last_synced_at": "2026-10-17T09:15:30.598Z", "location_count": 234, "location_summary": "Birmingham, Alabama • Casa Grande, Arizona • Sedona, Arizona + 205 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Casa Grande", "state": "Arizona" }, { "city": "Sedona", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00507416" }, { "nct_id": "NCT00633945", "title": "Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cutaneous Lupus Erythematosus (CLE)" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 5, "start_date": "2007-11", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2023-02-09", "last_synced_at": "2026-10-17T09:15:30.598Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00633945" }, { "nct_id": "NCT00002392", "title": "A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rockefeller University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-17T09:15:30.598Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002392" }, { "nct_id": "NCT00250796", "title": "Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver", "Cancer" ], "interventions": [ { "name": "Thalidomide, alpha interferon", "type": "DRUG" }, { "name": "Thalidomide, interferon, Octreotide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of New Mexico", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2000-09", "completion_date": "2006-03", "has_results": false, "last_update_posted_date": "2010-01-07", "last_synced_at": "2026-10-17T09:15:30.598Z", "location_count": 2, "location_summary": "Albuquerque, New Mexico • Santa Fe, New Mexico", "locations": [ { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Santa Fe", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT00250796" }, { "nct_id": "NCT00004088", "title": "Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "pamidronate disodium", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "65 Years", "sex": "ALL", "summary": "Up to 65 Years" }, "enrollment_count": 77, "start_date": "1999-04-13", "completion_date": "2018-01-09", "has_results": true, "last_update_posted_date": "2019-07-02", "last_synced_at": "2026-10-17T09:15:30.598Z", "location_count": 2, "location_summary": "Phoenix, Arizona • Duarte, California", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004088" }, { "nct_id": "NCT00274820", "title": "Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "ascorbic acid", "type": "DIETARY_SUPPLEMENT" }, { "name": "arsenic trioxide", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 15, "start_date": "2005-10", "completion_date": "2007-10", "has_results": false, "last_update_posted_date": "2020-07-27", "last_synced_at": "2026-10-17T09:15:30.598Z", "location_count": 2, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00274820" } ] }